|
1
|
Zhou F, Han S, Zhou N, Zheng W and Li P:
Effects of modified Shu-Gan-Liang-Xue decoction combined with
anastrozole on osteoblastic proliferation and differentiation of
MC3T3-E1 cells. Mol Med Rep. 11:1639–1646. 2015.PubMed/NCBI
|
|
2
|
Wilson S and Chia SK: Treatment algorithms
for hormone receptor-positive advanced breast cancer: Applying the
results from recent clinical trials into daily practice-insights,
limitations, and moving forward. Am Soc Clin Oncol Educ Book.
2013.doi: 10.1200/EdBook_AM.2013.33.e20. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Paridaens R, Thomas J, Wildiers J,
Vermeiren P, Lobelle JP, di Salle E, Ornati G, Zurlo MG, Polli A,
Lanzalone S and de Belder K: Safety, activity and estrogen
inhibition by exemestane in postmenopausal women with advanced
breast cancer: A phase I study. Anticancer Drugs. 9:675–683. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Van Asten K, Neven P, Lintermans A,
Wildiers H and Paridaens R: Aromatase inhibitors in the breast
cancer clinic: Focus on exemestane. Endocr Relat Cancer.
21:R31–R49. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Khosla S, Melton LJ III and Riggs BL: The
unitary model for estrogen deficiency and the pathogenesis of
osteoporosis: Is a revision needed? J Bone Miner Res. 26:441–451.
2011. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mazziotti G, Canalis E and Giustina A:
Drug-induced osteoporosis: Mechanisms and clinical implications. Am
J Med. 123:877–884. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
McCloskey EV, Hannon RA, Lakner G, Fraser
WD, Clack G, Miyamoto A, Finkelman RD and Eastell R: Effects of
third generation aromatase inhibitors on bone health and other
safety parameters: Results of an open, randomised, multi-centre
study of letrozole, exemestane and anastrozole in healthy
postmenopausal women. Eur J Cancer. 43:2523–2531. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hong AR, Kim JH, Lee KH, Kim TY, Im SA,
Kim TY, Moon HG, Han WS, Noh DY, Kim SW and Shin CS: Long-term
effect of aromatase inhibitors on bone microarchitecture and
macroarchitecture in non-osteoporotic postmenopausal women with
breast cancer. Osteoporos Int. 28:1413–1422. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fusi C, Materazzi S, Benemei S, Coppi E,
Trevisan G, Marone IM, Minocci D, De Logu F, Tuccinardi T, Di
Tommaso MR, et al: Steroidal and non-steroidal third-generation
aromatase inhibitors induce pain-like symptoms via TRPA1. Nat
Commun. 5:57362014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Winters-Stone KM, Dobek J, Nail L, Bennett
JA, Leo MC, Naik A and Schwartz A: Strength training stops bone
loss and builds muscle in postmenopausal breast cancer survivors: A
randomized, controlled trial. Breast Cancer Res Treat. 127:447–456.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Goss PE, Qi S, Cheung AM, Hu H, Mendes M
and Pritzker KP: Effects of the steroidal aromatase inhibitor
exemestane and the nonsteroidal aromatase inhibitor letrozole on
bone and lipid metabolism in ovariectomized rats. Clin Cancer Res.
10:5717–5723. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kumru S, Yildiz AA, Yilmaz B, Sandal S and
Gurates B: Effects of aromatase inhibitors letrozole and
anastrozole on bone metabolism and steroid hormone levels in intact
female rats. Gynecol Endocrinol. 23:556–561. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yonden Z, Aydin M, Alcin E, Kelestemur MH,
Kutlu S and Yilmaz B: Effects of letrozole on bone biomarkers and
femur fracture in female rats. J Physiol Biochem. 65:267–275. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Plourde PV, Dyroff M, Dowsett M, Demers L,
Yates R and Webster A: ARIMIDEX: A new oral, once-a-day aromatase
inhibitor. J Steroid Biochem Mol Biol. 53:175–179. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Crenshaw TD, Peo ER, Lewis AJ and Moser
BD: Bone Strength as a trait for assessing mineralization in swine:
A Critical Review of Techniques Involved. J Animal Science.
53:827–835. 1981. View Article : Google Scholar
|
|
16
|
Czajka-Oraniec I and Simpson ER: Aromatase
research and its clinical significance. Endokrynol Pol. 61:126–134.
2010.PubMed/NCBI
|
|
17
|
Gonzales RJ, Ansar S, Duckles SP and
Krause DN: Androgenic/estrogenic balance in the male rat cerebral
circulation: Metabolic enzymes and sex steroid receptors. J Cereb
Blood Flow Metab. 27:1841–1852. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Harada N, Sasano H, Murakami H, Ohkuma T,
Nagura H and Takagi Y: Localized expression of aromatase in human
vascular tissues. Circ Res. 84:1285–1291. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kim JH, Cho HT and Kim YJ: The role of
estrogen in adipose tissue metabolism: Insights into glucose
homeostasis regulation. Endocr J. 61:1055–1067. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tyrovola JB: The ‘Mechanostat Theory’ of
Frost and the OPG/RANKL/RANK System. J Cell Biochem. 116:2724–2729.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Briot K and Roux C: Drug-induced
osteoporosis: Beyond glucocorticoids. Curr Rheumatol Rep.
10:102–109. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Anastasilakis AD, Toulis KA, Polyzos SA
and Terpos E: RANKL inhibition for the management of patients with
benign metabolic bone disorders. Expert Opin Investig Drugs.
18:1085–1102. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Weitzmann MN: The Role of Inflammatory
Cytokines, the RANKL/OPG Axis and the Immunoskeletal Interface in
Physiological Bone Turnover and Osteoporosis. Scientifica (Cairo).
2013:1257052013.PubMed/NCBI
|
|
24
|
Folestad A, Ålund M, Asteberg S, Fowelin
J, Aurell Y, Göthlin J and Cassuto J: Role of Wnt/β-catenin and
RANKL/OPG in bone healing of diabetic Charcot arthropathy patients.
Acta Orthop. 86:415–425. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mezil YA, Allison D, Kish K, Ditor D, Ward
WE, Tsiani E and Klentrou P: Response of bone turnover markers and
cytokines to high-intensity low-impact exercise. Med Sci Sports
Exerc. 47:1495–1502. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Boyle WJ, Simonet WS and Lacey DL:
Osteoclast differentiation and activation. Nature. 423:337–342.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Taylan A, Sari I, Akinci B, Bilge S,
Kozaci D, Akar S, Colak A, Yalcin H, Gunay N and Akkoc N:
Biomarkers and cytokines of bone turnover: Extensive evaluation in
a cohort of patients with ankylosing spondylitis. BMC Musculoskelet
Disord. 13:1912012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Boyce BF and Xing L: Biology of RANK,
RANKL, and osteoprotegerin. Arthritis Res Ther. 9:(Suppl 1).
S12007. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Thomas GP, Baker SU, Eisman JA and
Gardiner EM: Changing RANKL/OPG mRNA expression in differentiating
murine primary osteoblasts. J Endocrinol. 170:451–460. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ostrowska Z, Ziora K, Oświęcimska J,
Swiętochowska E, Szapska B, Wołkowska-Pokrywa K and Dyduch A:
RANKL/RANK/OPG system and bone status in females with anorexia
nervosa. Bone. 50:156–160. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wasilewska A, Rybi-Szuminska AA and
Zoch-Zwierz W: Serum osteoprotegrin (OPG) and receptor activator of
nuclear factor kappaB (RANKL) in healthy children and adolescents.
J Pediatr Endocrinol Metab. 22:1099–1104. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fyhrie DP and Vashishth D: Bone stiffness
predicts strength similarly for human vertebral cancellous bone in
compression and for cortical bone in tension. Bone. 26:169–173.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Goulet RW, Goldstein SA, Ciarelli MJ, Kuhn
JL, Brown MB and Feldkamp LA: The relationship between the
structural and orthogonal compressive properties of trabecular
bone. J Biomech. 27:375–389. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hooshmand S, Kern M, Metti D, Shamloufard
P, Chai SC, Johnson SA, Payton ME and Arjmandi BH: The effect of
two doses of dried plum on bone density and bone biomarkers in
osteopenic postmenopausal women: A randomized, controlled trial.
Osteoporos Int. 27:2271–2279. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zioupos P and Currey JD: Changes in the
stiffness, strength, and toughness of human cortical bone with age.
Bone. 22:57–66. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Vegger JB, Brüel A, Sørensen TG and
Thomsen JS: Systemic treatment with strontium ranelate does not
influence the healing of femoral mid-shaft defects in rats. Calcif
Tissue Int. 98:206–214. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Naruse K, Uchida K, Suto M, Miyagawa K,
Kawata A, Urabe K, Takaso M, Itoman M and Mikuni-Takagaki Y:
Alendronate does not prevent long bone fragility in an inactive rat
model. J Bone Miner Metab. 34:615–626. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gasser JA, Green JR, Shen V, Ingold P,
Rebmann A, Bhatnagar AS and Evans DB: A single intravenous
administration of zoledronic acid prevents the bone loss and
mechanical compromise induced by aromatase inhibition in rats.
Bone. 39:787–795. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sengupta P: The laboratory rat: relating
its age with human's. Int J Prev Med. 4:624–630. 2013.PubMed/NCBI
|
